Massachusetts Biomedical Initiatives

O'Sullivan is something of a godfather for the biomanufacturing surge in Worcester, having run the MBI incubator for 33 years and playing an active role in Worcester redevelopment efforts through the Economic Development Coordinating Council.

According to Kevin O'Sullivan, the head of MBI, Worcester has arrived as a biotech destination with the recent announcement of a Chinese biotech's planned $60 million facility.

The chief executive of Worcester incubator Massachusetts Biomedical Initiatives is on the verge of realizing his longtime vision for the city.

With Reliant's potential sale – its board is voting on May 9 – fears over the ceding of local control need to be balanced with the realities of a changing healthcare industry: costs must come down and providers must find further efficiencies.

With venture capitalists largely ignoring Central Massachusetts, the startup industry hopes new services keep companies local.

Two decades ago, Kevin O'Sullivan worked with a small biotech company named Valeritas in his Worcester incubator Massachusetts Biomedical Initiatives on what felt like groundbreaking technology at a time – a wearable insulin-dispensing device for Type 2 diabetes.

O'Sullivan has been promoting biotechnology in Central Massachusetts for years and has helped it grow into what it is today.

The city of Worcester's Economic Development Coordinating Council is in talks with a California company to make it the first resident of a biomanufacturing site.

The U.S. Small Business Administration has awarded $50,000 to Worcester's to Massachusetts Biomedical Initiatives as part of $3.4 million in national funding.

The Baker Administration has selected the Worcester Business Development Corp. to redevelop 44 acres of land on the former Worcester State Hospital Campus into a biomanufacturing facility that could employ up to 500 people.